These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 19471894)

  • 1. Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model.
    Kim HM; Kang JS; Lim J; Kim JY; Kim YJ; Lee SJ; Song S; Hong JT; Kim Y; Han SB
    Arch Pharm Res; 2009 May; 32(5):781-7. PubMed ID: 19471894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of human cervical carcinoma growth by cytokine-induced killer cells in nude mouse xenograft model.
    Kim HM; Lim J; Kang JS; Park SK; Lee K; Kim JY; Kim YJ; Hong JT; Kim Y; Han SB
    Int Immunopharmacol; 2009 Mar; 9(3):375-80. PubMed ID: 19105981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells.
    Kim YJ; Lim J; Kang JS; Kim HM; Lee HK; Ryu HS; Kim JY; Hong JT; Kim Y; Han SB
    Arch Pharm Res; 2010 Nov; 33(11):1789-95. PubMed ID: 21116782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of cytokine-induced killer cells against human lung cancer.
    Kim HM; Lim J; Park SK; Kang JS; Lee K; Lee CW; Lee KH; Yun MJ; Yang KH; Han G; Kwon SW; Kim Y; Han SB
    Int Immunopharmacol; 2007 Dec; 7(13):1802-7. PubMed ID: 17996691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma.
    Kim HM; Lim J; Yoon YD; Ahn JM; Kang JS; Lee K; Park SK; Jeong YJ; Kim JM; Han G; Yang KH; Kim YJ; Kim Y; Han SB
    Int Immunopharmacol; 2007 Dec; 7(13):1793-801. PubMed ID: 17996690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Growth inhibition of human hepatocellular carcinoma xenograft in nude mice by combined treatment with human cytokine-induced killer cells and chemotherapy].
    Shi M; Yao L; Wang FS; Lei ZY; Zhang B; Li WL; Liu JC; Tang ZR; Zhou GD
    Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):465-8. PubMed ID: 15555334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental study on the treatment of intracerebral glioma xenograft with human cytokine-induced killer cells.
    Wang P; Yu JP; Gao SY; An XM; Ren XB; Wang XG; Li WL
    Cell Immunol; 2008; 253(1-2):59-65. PubMed ID: 18522858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
    Lu PH; Negrin RS
    J Immunol; 1994 Aug; 153(4):1687-96. PubMed ID: 7519209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses.
    Zhu BQ; Ju SW; Shu YQ
    Biomed Pharmacother; 2009 Aug; 63(7):509-16. PubMed ID: 19019623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human cytokine-induced killer cells specifically infiltrated and retarded the growth of the inoculated human cholangiocarcinoma cells in SCID mice.
    Wongkajornsilp A; Somchitprasert T; Butraporn R; Wamanuttajinda V; Kasetsinsombat K; Huabprasert S; Maneechotesuwan K; Hongeng S
    Cancer Invest; 2009 Feb; 27(2):140-8. PubMed ID: 19235585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.
    Schmidt-Wolf IG; Lefterova P; Mehta BA; Fernandez LP; Huhn D; Blume KG; Weissman IL; Negrin RS
    Exp Hematol; 1993 Dec; 21(13):1673-9. PubMed ID: 7694868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas.
    Weng DS; Zhou J; Zhou QM; Zhao M; Wang QJ; Huang LX; Li YQ; Chen SP; Wu PH; Xia JC
    J Immunother; 2008 Jan; 31(1):63-71. PubMed ID: 18157013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.
    Leemhuis T; Wells S; Scheffold C; Edinger M; Negrin RS
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):181-7. PubMed ID: 15744236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma.
    Yuan X; Hu J; Belladonna ML; Black KL; Yu JS
    Cancer Res; 2006 Mar; 66(5):2630-8. PubMed ID: 16510582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Coculture of dendritic cell with cytokine-induced killer results in a significant increase in cytotoxic activity of CIK to tumor cells in vitro and in vivo].
    Ge W; Li CH; Zhang W; Han Q; Deng WM; Chen L; You SG; Zhao CH
    Zhonghua Xue Ye Xue Za Zhi; 2004 May; 25(5):277-80. PubMed ID: 15182535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model.
    Du X; Jin R; Ning N; Li L; Wang Q; Liang W; Liu J; Xu Y
    Oncol Rep; 2012 Nov; 28(5):1743-9. PubMed ID: 22948809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene.
    Finke S; Trojaneck B; Lefterova P; Csipai M; Wagner E; Kircheis R; Neubauer A; Huhn D; Wittig B; Schmidt-Wolf IG
    Gene Ther; 1998 Jan; 5(1):31-9. PubMed ID: 9536262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thymoglobulin efficiently expands cytokine-induced killer cells in a clinical-grade culture protocol].
    Chen W; Lin D; Jiang Z; Yang Z; Song S; Zhou J; Zhou L; Sun Y; Yu H; Ma D
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):681-5, 690. PubMed ID: 25001928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.